In the present study, we identified that the expression of Ano1 was higher in PR-positive tumors compared with PR-negative tumors, especially in the ER-negative patients, suggesting that the ER and PR signaling pathways may be involved in Ano1 overexpression in breast cancer. Here, ANO1 is linked to breast carcinoma.